Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity.

Reitinger, Carmen; Ipsen-Escobedo, Andrea; Hornung, Chiara; Heger, Lukas; Dudziak, Diana; Lux, Anja; Nimmerjahn, Falk

Reitinger, Carmen; Ipsen-Escobedo, Andrea; Hornung, Chiara; Heger, Lukas; Dudziak, Diana; Lux, Anja; Nimmerjahn, Falk.

Afiliación

Reitinger C; Chair of Genetics, Department of Biology, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Ipsen-Escobedo A; Chair of Genetics, Department of Biology, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Hornung C; Chair of Genetics, Department of Biology, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Heger L; Laboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Dudziak D; Laboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Lux A; Medical Immunology Campus Erlangen, Erlangen, Germany.
Nimmerjahn F; Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany.

Front Immunol ; 13: 970290, 2022.

Article en En | MEDLINE | ID: mdl-36248847

Asunto(s)

Anticuerpos Monoclonales; Receptores de IgG; Animales; Anticuerpos Monoclonales/farmacología; Glicosilación; Humanos; Inmunoglobulina G; Ratones; Receptores de IgG/metabolismo

Palabras clave

CD137; Fc-receptors; glycosylation; therapeutic antibody; urelumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Receptores de IgG / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google